Anna Pellat retweeted
In this study @Sallyyac1 and colleagues examine the characteristics of comparative non-randomised studies that assess the effectiveness or safety, or both, of drug treatments.
Read the full research article here: bit.ly/4hsgGfu
@AnnaPellat @thitran3 @IsabelleBoutron
Anna Pellat retweeted
馃敍 @myESMO webinar on #RWD & #DigitalOncology
馃帣锔弇oderated by @AnnaPellat & Carola Schulz, ft. @AliceFranzoi, Danielle Seinstra, & Henrique Martins 馃挮
鉁旓笍 #Oncology #RWD: challenges & opportunities
鉁旓笍 Needs in 1ary #data collection & sharing
鉁旓笍 馃嚜馃嚭 Electronic #HealthRecord Format
Anna Pellat retweeted
Brainstorming on EnLiST, the @myESMO ESMO Adaptation of Lines of Systemic Therapy, with Chris Twelves, Kamal Saini, Miriam Koopman, Suzette Delaloze, the ESMO Real World Data Digital Working Group and individual experts from EMA FDA Industry EORTC CRO Patient Advocates
Anna Pellat retweeted
ESMO-GROW is a guidance to homogenize reporting of Real World Data, in order to generate robust Real World Evidence. This includes general recommendations, how to report patient selection and recommendations about Data to include. Wide adoption will make RWD more impactful
ESMO announces the publication of ESMO-GROW, the first oncology-specific reporting guidance for #RWEstudies, representing a key step forward to increase quality standards and harmonised interpretations in RWD publications in #oncology.
馃憠ow.ly/Aj6a50PWZUZ
Anna Pellat retweeted
馃摙 #ESMOGROW is the 1鈨t #reporting guidance specifically for #RWEstudies in #oncology
鈥硷笍 out in @Annals_Oncology and @myESMO Real World Data and Digital Oncology
馃敐 teamwork led by @LuisCB_MedPharm 馃挮and supervised by Pr @GPentheroudakis, Dr Suzette Delaloge, and @Prof_Koopman
ESMO announces the publication of ESMO-GROW, the first oncology-specific reporting guidance for #RWEstudies, representing a key step forward to increase quality standards and harmonised interpretations in RWD publications in #oncology.
馃憠ow.ly/Aj6a50PWZUZ










